Cargando…

Improving the process of ordering outside genomic testing for lung cancer FNA and small biopsy specimens – A multidisciplinary quality improvement project

OBJECTIVES: Lung cancer is an important cause of mortality in the United States. Targeted mutation analysis has the potential to alter mortality in those with non-small-cell lung cancer. As such, the importance of timely tissue turnaround time (TAT) is substantial. We evaluated TAT at Mayo Clinic Ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Nokes, Brandon, Baumann, Coralie, Magallanez, Kim, Cartin-Ceba, Rodrigo, Spiczka, Amy Wendel Wendel, Malhotra, Atul, Chen, Longwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Scientific Scholar 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10159331/
https://www.ncbi.nlm.nih.gov/pubmed/37151481
http://dx.doi.org/10.25259/Cytojournal_47_2021
_version_ 1785037118001643520
author Nokes, Brandon
Baumann, Coralie
Magallanez, Kim
Cartin-Ceba, Rodrigo
Spiczka, Amy Wendel Wendel
Malhotra, Atul
Chen, Longwen
author_facet Nokes, Brandon
Baumann, Coralie
Magallanez, Kim
Cartin-Ceba, Rodrigo
Spiczka, Amy Wendel Wendel
Malhotra, Atul
Chen, Longwen
author_sort Nokes, Brandon
collection PubMed
description OBJECTIVES: Lung cancer is an important cause of mortality in the United States. Targeted mutation analysis has the potential to alter mortality in those with non-small-cell lung cancer. As such, the importance of timely tissue turnaround time (TAT) is substantial. We evaluated TAT at Mayo Clinic Arizona and found it to be delayed relative to national standards. MATERIAL AND METHODS: We conducted a series of plan, do, study, and act (PDSA) cycles at a single institution to identify areas for improvement with our lung cancer genomic testing. We assembled a multidisciplinary team and held serial meetings to discuss data from each PDSA cycle. RESULTS: Using PDSA cycles and multidisciplinary discussions, we were able to identify a number of process limitations slowing TAT. We were then able to generate enhanced and timely communication between providers and pathology, educate and enforce the order/requisition workflow, and establish pathology accessioning with lung cancer specimens top priority. CONCLUSION: We were able to generate and implement a standard operating procedure for genomic testing of lung cancer specimens at our institution, thereby reducing tissue TAT.
format Online
Article
Text
id pubmed-10159331
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Scientific Scholar
record_format MEDLINE/PubMed
spelling pubmed-101593312023-05-05 Improving the process of ordering outside genomic testing for lung cancer FNA and small biopsy specimens – A multidisciplinary quality improvement project Nokes, Brandon Baumann, Coralie Magallanez, Kim Cartin-Ceba, Rodrigo Spiczka, Amy Wendel Wendel Malhotra, Atul Chen, Longwen Cytojournal Research Article OBJECTIVES: Lung cancer is an important cause of mortality in the United States. Targeted mutation analysis has the potential to alter mortality in those with non-small-cell lung cancer. As such, the importance of timely tissue turnaround time (TAT) is substantial. We evaluated TAT at Mayo Clinic Arizona and found it to be delayed relative to national standards. MATERIAL AND METHODS: We conducted a series of plan, do, study, and act (PDSA) cycles at a single institution to identify areas for improvement with our lung cancer genomic testing. We assembled a multidisciplinary team and held serial meetings to discuss data from each PDSA cycle. RESULTS: Using PDSA cycles and multidisciplinary discussions, we were able to identify a number of process limitations slowing TAT. We were then able to generate enhanced and timely communication between providers and pathology, educate and enforce the order/requisition workflow, and establish pathology accessioning with lung cancer specimens top priority. CONCLUSION: We were able to generate and implement a standard operating procedure for genomic testing of lung cancer specimens at our institution, thereby reducing tissue TAT. Scientific Scholar 2023-04-05 /pmc/articles/PMC10159331/ /pubmed/37151481 http://dx.doi.org/10.25259/Cytojournal_47_2021 Text en © 2023 Cytopathology Foundation Inc, Published by Scientific Scholar https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Research Article
Nokes, Brandon
Baumann, Coralie
Magallanez, Kim
Cartin-Ceba, Rodrigo
Spiczka, Amy Wendel Wendel
Malhotra, Atul
Chen, Longwen
Improving the process of ordering outside genomic testing for lung cancer FNA and small biopsy specimens – A multidisciplinary quality improvement project
title Improving the process of ordering outside genomic testing for lung cancer FNA and small biopsy specimens – A multidisciplinary quality improvement project
title_full Improving the process of ordering outside genomic testing for lung cancer FNA and small biopsy specimens – A multidisciplinary quality improvement project
title_fullStr Improving the process of ordering outside genomic testing for lung cancer FNA and small biopsy specimens – A multidisciplinary quality improvement project
title_full_unstemmed Improving the process of ordering outside genomic testing for lung cancer FNA and small biopsy specimens – A multidisciplinary quality improvement project
title_short Improving the process of ordering outside genomic testing for lung cancer FNA and small biopsy specimens – A multidisciplinary quality improvement project
title_sort improving the process of ordering outside genomic testing for lung cancer fna and small biopsy specimens – a multidisciplinary quality improvement project
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10159331/
https://www.ncbi.nlm.nih.gov/pubmed/37151481
http://dx.doi.org/10.25259/Cytojournal_47_2021
work_keys_str_mv AT nokesbrandon improvingtheprocessoforderingoutsidegenomictestingforlungcancerfnaandsmallbiopsyspecimensamultidisciplinaryqualityimprovementproject
AT baumanncoralie improvingtheprocessoforderingoutsidegenomictestingforlungcancerfnaandsmallbiopsyspecimensamultidisciplinaryqualityimprovementproject
AT magallanezkim improvingtheprocessoforderingoutsidegenomictestingforlungcancerfnaandsmallbiopsyspecimensamultidisciplinaryqualityimprovementproject
AT cartincebarodrigo improvingtheprocessoforderingoutsidegenomictestingforlungcancerfnaandsmallbiopsyspecimensamultidisciplinaryqualityimprovementproject
AT spiczkaamywendelwendel improvingtheprocessoforderingoutsidegenomictestingforlungcancerfnaandsmallbiopsyspecimensamultidisciplinaryqualityimprovementproject
AT malhotraatul improvingtheprocessoforderingoutsidegenomictestingforlungcancerfnaandsmallbiopsyspecimensamultidisciplinaryqualityimprovementproject
AT chenlongwen improvingtheprocessoforderingoutsidegenomictestingforlungcancerfnaandsmallbiopsyspecimensamultidisciplinaryqualityimprovementproject